175 related articles for article (PubMed ID: 1591921)
41. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ
Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316
[TBL] [Abstract][Full Text] [Related]
42. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
43. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
[TBL] [Abstract][Full Text] [Related]
44. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
45. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women.
Basdevant A; Pelissier C; Conard J; Degrelle H; Guyene TT; Thomas JL
Contraception; 1991 Dec; 44(6):599-605. PubMed ID: 1773617
[TBL] [Abstract][Full Text] [Related]
46. Review of newer contraceptive agents.
Qureshi M; Attaran M
Cleve Clin J Med; 1999 Jun; 66(6):358-66. PubMed ID: 10375845
[TBL] [Abstract][Full Text] [Related]
47. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.
Lähteenmäki PL; Lähteenmäki P
Fertil Steril; 1985 Jul; 44(1):20-4. PubMed ID: 3924666
[TBL] [Abstract][Full Text] [Related]
48. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
49. Transdermal application of steroid hormones for contraception.
Sitruk-Ware R
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):247-51. PubMed ID: 7626463
[TBL] [Abstract][Full Text] [Related]
50. Intravaginal contraception with the synthetic progestin, R2323.
Akinla O; Lähteenmäki P; Jackanicz TM
Contraception; 1976 Dec; 14(6):671-8. PubMed ID: 1017201
[TBL] [Abstract][Full Text] [Related]
51. Clinical results with subcutaneous implants containing 3-keto desogestrel.
Olsson SE; Odlind V; Johansson E
Contraception; 1990 Jul; 42(1):1-11. PubMed ID: 2117514
[TBL] [Abstract][Full Text] [Related]
52. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception.
Glasier A; Thong KJ; Dewar M; Mackie M; Baird DT
N Engl J Med; 1992 Oct; 327(15):1041-4. PubMed ID: 1522839
[TBL] [Abstract][Full Text] [Related]
53. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
54. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
55. Ovulation detection following removal of levonorgestrel subdermal contraceptive implants.
Ismail AA; Anwar MY; Youssef SM; Toppozada M
Contraception; 1987 Mar; 35(3):207-14. PubMed ID: 3111783
[TBL] [Abstract][Full Text] [Related]
56. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill.
Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1982 Jan; 25(1):13-30. PubMed ID: 7060371
[No Abstract] [Full Text] [Related]
57. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
58. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
59. Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception.
Subakir SB; Hadisaputra W; Siregar B; Irawati D; Santoso DI; Cornain S; Affandi B
Hum Reprod; 1995 Oct; 10(10):2579-83. PubMed ID: 8567774
[TBL] [Abstract][Full Text] [Related]
60. Serum estrogens and ovulation return in chronic users of a once-a-month injectable contraceptive.
Schiavon R; Benavides S; Oropeza G; Garza-Flores J; Recio R; Díaz-Sanchez V; Pérez-Palacios G
Contraception; 1988 Jun; 37(6):591-8. PubMed ID: 3396358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
